Evidence map›Paper›PMID 38795244›Full record

ArticleDoklady. Biochemistry and biophysics2024

Binary Proton Therapy of Ehrlich Carcinoma Using Targeted Gold Nanoparticles.

M V Filimonova, D D Kolmanovich, G V Tikhonowski, D S Petrunya, P A Kotelnikova, A A Shitova, O V Soldatova, A S Filimonov, V A Rybachuk, A O Kosachenko and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Polyacrylic Acid-Coated LaBPharmaceutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

M V FilimonovaTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
D D KolmanovichInstitute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Russia.
G V TikhonowskiNational Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russia.
D S PetrunyaLebedev Physical Institute, Russian Academy of Sciences, Moscow, Russia. d.petrunya@lebedev.ru.
P A KotelnikovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
A A ShitovaTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
O V SoldatovaTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
A S FilimonovTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
V A RybachukTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
A O KosachenkoTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
K A NikolaevTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
G A DemyashkinTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
A A PopovNational Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russia.
M S SavinovNational Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russia.
A L PopovInstitute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Russia.
I V ZelepukinShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
A A LipengoltsNational Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russia.
K E ShpakovaNational Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russia.
A V KabashinAix-Marseille University, CNRS, Marseille, France.
S N KoryakinTsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
S M DeyevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
I N ZavestovskayaLebedev Physical Institute, Russian Academy of Sciences, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton therapy can treat tumors located in radiation-sensitive tissues. This article demonstrates the possibility of enhancing the proton therapy with targeted gold nanoparticles that selectively recognize tumor cells. Au-PEG nanoparticles at concentrations above 25 mg/L and 4 Gy proton dose caused complete death of EMT6/P cells in vitro. Binary proton therapy using targeted Au-PEG-FA nanoparticles caused an 80% tumor growth inhibition effect in vivo. The use of targeted gold nanoparticles is promising for enhancing the proton irradiation effect on tumor cells and requires further research to increase the therapeutic index of the approach.

Indexed as

Carcinoma, Ehrlich TumorGoldMetal NanoparticlesProton TherapyAnimalsCell Line, TumorMicePolyethylene GlycolsGoldPolyethylene Glycolsgoldnanoparticlesproton therapyradiosensitizerstumor therapy

Identifiers

PMID38795244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.